THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha(R) (evolocumab injection) for eligible ...
Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
Repatha (evolocumab) is a prescription drug used in certain situations to lower cholesterol and reduce serious heart-related risks. Repatha does this by attaching itself to a protein in your body ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results